July 20, 2022

Theratechnologies Inc., a Montreal based biopharmaceutical company focused on the development and commercialization of innovative therapies, secured a $100 million non-dilutive term loan from Marathon Asset Management. A portion of the loan proceeds will be used to repurchase some of the company’s outstanding convertible notes. The Credit Agreement was signed on July 20th.

Partners Martin C. Glass and Brian S. Hart led the deal team with support fromand Associates William R. Erlain and Sadie M. Shourd and Kristen M. Iglesias.